VistaGen Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by VistaGen Therapeutics, Inc. on January 5, 2021. The report addresses a specific regulatory event regarding the company's listing status on the Nasdaq Capital Market under the trading symbol VTGN.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a compliance event related to the company's stock price.
Material Changes
The primary material change reported is the resolution of a listing deficiency. The Nasdaq Listing Qualifications Staff determined that the company regained full compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)) because the closing bid price of its common stock exceeded $1.00 per share for 10 consecutive trading days. Consequently, the matter regarding the previous deficiency is now closed.
Outlook, Risks, and Management Commentary
Management commentary is limited to the confirmation of regained compliance. A press release issued on January 6, 2021, regarding this event is attached as Exhibit 99.1. The filing does not contain new guidance, updated risk factors, or discussion of contingencies beyond the resolution of the listing issue.
Key Facts for Investor Verification
- The company has regained full compliance with Nasdaq minimum bid price requirements.
- The compliance was achieved based on the stock price remaining above $1.00 for 10 consecutive trading days.
- The specific date of the Nasdaq determination letter was January 5, 2021.
- No financial performance data is included in this specific filing.